Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-2345 vs Xalatan in Glaucoma or Ocular Hypertension
NCT02059278Phase 3Completed
- Sponsor
- Nephron Pharmaceuticals Corporation
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Nephron Pharmaceuticals Corporation. Primary endpoint: Intraocular Pressure at Day 84. Started Jan 2014; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02059278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059278.